TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
Want to see HK:1875 full AI Analyst Report?
Top Page
TOT BIOPHARM International Co. Ltd.
(1875)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$5.00
▲(100.00% Upside)
Action:Reiterated
Date:05/11/26
The score is held back primarily by weak 2025 financial performance (revenue decline, return to losses, and persistently negative free cash flow). Offsetting this is a constructive technical backdrop with price trading above key moving averages and neutral-to-positive momentum indicators. Valuation remains challenged due to loss-making status (negative P/E).
Positive Factors
Diversified revenue streams
The business earns revenue from product sales and from contract development & GMP manufacturing services, plus potential licensing. This durable mix reduces reliance on a single commercial product, creates multiple revenue levers, and can stabilize cash receipts across product cycles.
Negative Factors
Revenue and profit deterioration
A large YoY revenue drop and reversion to losses signals weakening commercial traction or product/mix disruption. Over 2–6 months this undermines margin sustainability, reduces internal funding for R&D and commercialization, and raises execution risk for restoring prior growth trajectories.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
The business earns revenue from product sales and from contract development & GMP manufacturing services, plus potential licensing. This durable mix reduces reliance on a single commercial product, creates multiple revenue levers, and can stabilize cash receipts across product cycles.
Read all positive factors
TOT BIOPHARM International Co. Ltd. (1875) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.51B
Dividend YieldN/A
Average Volume (3M)240.51K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth-32.12%
EPS Growth-393.23%
CountryHK
Employees611
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$1.61B
TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model
Company Description
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The co...
How the Company Makes Money
The company makes money primarily through (1) sales of pharmaceutical products, where revenue is generated from distributing and selling its oncology-focused medicines (including specialty/complex injectables and related anti-cancer therapeutics) ...
TOT BIOPHARM International Co. Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 747.64M | 1.10B | 780.63M | 442.18M | 76.33M |
| Gross Profit | 388.98M | 782.43M | 573.99M | 370.62M | 27.47M |
| EBITDA | -6.44M | 84.96M | 10.45M | -5.41M | -224.51M |
| Net Income | -100.37M | 34.76M | -37.76M | -49.92M | -261.22M |
Balance Sheet | |||||
| Total Assets | 1.26B | 1.51B | 1.43B | 1.26B | 710.26M |
| Cash, Cash Equivalents and Short-Term Investments | 328.47M | 381.26M | 351.60M | 517.63M | 155.38M |
| Total Debt | 383.72M | 395.47M | 345.65M | 289.53M | 208.56M |
| Total Liabilities | 633.75M | 779.12M | 739.41M | 546.59M | 375.17M |
| Stockholders Equity | 626.08M | 729.65M | 686.69M | 713.88M | 335.09M |
Cash Flow | |||||
| Free Cash Flow | -26.93M | -7.17M | -146.77M | -180.19M | -290.45M |
| Operating Cash Flow | 16.14M | 116.40M | 56.43M | 59.93M | -175.14M |
| Investing Cash Flow | -43.07M | -122.50M | -164.10M | -282.76M | -108.39M |
| Financing Cash Flow | -25.66M | 34.18M | 38.23M | 481.24M | 212.08M |
TOT BIOPHARM International Co. Ltd. Technical Analysis
Neutral
2.50
Price Trends
4.76
Negative
4.14
Positive
3.14
Positive
Market Momentum
-0.06
Positive
38.34
Neutral
13.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Neutral. The current price of 2.5 is below the 20-day moving average (MA) of 4.71, below the 50-day MA of 4.76, and below the 200-day MA of 3.14, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 38.34 is Neutral, neither overbought nor oversold. The STOCH value of 13.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1875.
TOT BIOPHARM International Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$3.51B | -3.96 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$1.83B | -2.75 | -39.41% | ― | ― | 39.48% | |
49 Neutral | HK$2.10B | 8.68 | 43.89% | ― | 150.60% | ― | |
47 Neutral | HK$1.45B | -4.01 | -12.64% | ― | -53.85% | 12.23% | |
45 Neutral | HK$924.98M | -7.27 | -15.19% | ― | ― | 20.16% | |
41 Neutral | HK$512.53M | -3.95 | 293.08% | ― | ― | -25.79% |
* Healthcare Sector Average
HK:1875
TOT BIOPHARM International Co. Ltd.
4.37
2.54
138.80%
HK:2181
Mabpharm Limited
0.45
<0.01
1.14%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
3.50
0.94
36.72%
HK:6622
Zhaoke Ophthalmology Ltd.
2.67
0.25
10.33%
HK:6978
Immunotech Biopharm Ltd
0.84
-2.14
-71.81%
HK:2511
Hightide Therapeutics Inc
3.45
0.60
21.05%
TOT BIOPHARM International Co. Ltd. Corporate Events
BioDlink Sets Out Board Composition and Key Committee Roles
Apr 28, 2026
BioDlink International Company Limited has announced the current composition of its board of directors and clarified the roles and functions of each member. The company has also detailed the makeup of its four key board committees—Audit and ...
BioDlink Overhauls Board After WuXi XDC Takes Control
Apr 28, 2026
BioDlink International Company Limited announced a sweeping board overhaul following a change in control after voluntary general cash offers resulted in WuXi XDC Cayman Inc. becoming its controlling shareholder. With effect from 29 April 2026, the...
WUXI XDC Gains Majority Control of TOT BIOPHARM After Cash Offers Close
Mar 31, 2026
WUXI XDC Cayman Inc., through BioDlink International Company Limited, has closed its voluntary conditional cash offers for all issued shares and outstanding share options of TOT BIOPHARM, excluding those already held by the offeror and its concert...
BioDlink’s CDMO Shift Cushions Revenue Fall as ADC and Global Push Gain Traction
Mar 18, 2026
BioDlink reported 2025 operating revenue of RMB747.6 million, down 32% year-on-year, as product sales fell 44% amid intensified market competition, while CDMO revenue grew 13% to RMB234.9 million. The company said CDMO has become its strategic sta...
WUXI XDC Unit Secures Control of TOT BIOPHARM as Cash Offers Turn Unconditional
Mar 17, 2026
WUXI XDC Cayman Inc., through its unit BioDlink International Company Limited, has launched voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd. that it does not already own and to cancel all outsta...
Wuxi XDC’s Cash Offer for TOT BIOPHARM Falls Short of Control Threshold, Offer Extended
Mar 13, 2026
Wuxi XDC Cayman Inc., through its offer vehicle BioDlink International Company Limited, has launched voluntary conditional cash offers for all issued shares and outstanding share options of TOT BIOPHARM International Co. Ltd. not already owned by ...
BioDlink Sets March Board Meeting to Approve 2025 Annual Results
Mar 5, 2026
BioDlink International Company Limited has scheduled a board meeting for 18 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The meeting may also address other corporate matters, sign...
BioDlink Clarifies Outstanding Share Options Amid Takeover Process
Mar 3, 2026
BioDlink International Company Limited has issued a clarification related to its earlier disclosure under Rule 3.8 of the Hong Kong Takeovers Code, in the context of ongoing takeover offers involving Wuxi Biologics. The board clarified that, follo...
BioDlink Posts Unaudited 2025 Figures Early as Net Assets Decline
Mar 3, 2026
BioDlink International Company Limited has released selected unaudited consolidated financial figures for the year ended 31 December 2025 ahead of its formal results, driven by disclosure obligations of its Taiwan-listed major shareholder Center L...
BioDlink updates capital structure and disclosure duties amid Wuxi Biologics offer
Mar 1, 2026
BioDlink International Company Limited has updated the market on changes to its capital structure during an ongoing takeover offer involving Wuxi Biologics, confirming that 142,000 share options vested on 1 March 2026 and providing an updated coun...
WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM
Feb 11, 2026
WuXi XDC Cayman Inc. has formally dispatched the composite offer and response document for its voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd., excluding those already held or agreed to be acqu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.